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Abstract
Objective: The purpose of this study was to assess psychometric properties of the six-item Headache Impact Text
(HIT-6
TM) across episodic and chronic migraine.
Methods: Using a migraine screener and number of headache days per month (HDPM), participants from the National
Survey of Headache Impact (NSHI) study and the HIT-6 validation study (HIT6-V) were selected for this study. Eligible
participants were categorized into three groups: chronic migraine (CM: 15 HDPM); episodic migraine (EM:<15
HDPM); non-migraine headaches. Reliability and validity of the HIT-6 were evaluated.
Results: A total of 2,049 survey participants met the inclusion/exclusion criteria for this study. Participants were identified
as 6.4% CM; 42.1% EM; 51.5% non-migraine, with respective mean HIT-6 scores: 62.5 7.8; 60.2 6.8; and 49.1 8.7.
High reliability was demonstrated with internal consistency (time1/time2) of 0.83/0.87 in NSHI, and 0.82/0.92 in HIT6-V.
Intra-class correlation for test-retest reliability was very good at 0.77. HIT-6 scores correlated significantly (p<.0001)
with total Migraine Disability Assessment Scale scores (r¼0.56), headache pain severity (r¼0.46), and HDPM (r¼0.29).
Discriminant validity analysis showed significantly different HIT-6 scores (F¼488.02, p<.0001) across the groups.
Conclusion: Results from these analyses confirm that the HIT-6 is a reliable and valid tool for discriminating headache
impact across episodic and chronic migraine.
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Introduction
Migraine is a prevalent and disabling condition that
aﬀects approximately 12% of the population in the
Western countries (1,2). The detrimental eﬀects of
migraine are well documented. Migraine interferes
with an individual’s physical functioning, work produc-
tivity, leisure activities, lifestyle and psychological well-
being (3–7). Furthermore, research has shown that the
level of disability diﬀers according to frequency of
headache events. According to Bigal and Lipton
(8–10), many patients with migraine can experience
the disease progression clinically, physiologically, and
anatomically. The typical clinical progression of
migraine is deﬁned by the frequency of headache
days. Individuals with episodic migraine (EM), deﬁned
as having <15 headache days per month (HDPM), may
progress to chronic migraine (CM), deﬁned as  15
HDPM (8–10). While the pathophysiology of the
transformation from episodic to chronic migraine is not
well understood, CM has been shown to be signiﬁcantly
more debilitating than episodic migraine (3,6,11).
Regardless of its disruptive eﬀect, migraine is fre-
quently underdiagnosed and undertreated (2,6,12). A
potential reason, as proposed by Bigal et al. (6), is the
lack of physician conﬁdence in the diagnosis of chronic
headache conditions and their subtypes. The International
Classiﬁcation of Headache Disorders, second edition
(ICHD-II) (13), introduced diagnostic criteria
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criteria were reﬁned and revised to more accurately
reﬂect the large majority of CM patients seen in clinical
practice (14).
Outcome measures to capture the impact of the dis-
order, beyond the frequency of headache episodes or
headache days, have been recommended and used by
clinical experts (15–18). These measures have most
commonly been used in studies of acute and prophy-
lactic treatments for episodic migraine. Few trials have
reported evaluation of treatments for CM (14). Clinical
evaluation of migraine-related disability or quality of
life plays an important role in migraine research and
patient management in clinical practice. To our knowl-
edge, none of the measures that evaluate disability or
quality of life have been psychometrically validated for
diﬀerentiating between the persons with EM disorder
(<15 HDPM) and CM disorder ( 15 HDPM).
The six-item Headache Impact Test (HIT-6) was
designed to provide a global measure of adverse head-
ache impact (19,20) and was developed to use in screen-
ing and monitoring patients with headaches in both
clinical practice and clinical research (20). The HIT-6
items measure the adverse impact of headache on social
functioning, role functioning, vitality, cognitive func-
tioning and psychological distress. The HIT-6 also
measures the severity of headache pain. The six items
were selected from 89 items (54 from an existing
adverse headache impact item pool and 35 items rec-
ommended by clinicians) (20). The HIT-6 shows good
internal consistency and test-retest reliability, construct
validity and responsiveness in general headache
patients (19–21). Since its initial development and val-
idation, the HIT-6 has been well received and widely
utilized in clinical practice, and applied to clinical trials
for patient screening and treatment monitoring of
headaches, including migraine (22–28).
The HIT-6 was developed among headache suﬀerers
with diﬀerent headache day frequency and severity
levels. Given the increasing use of the HIT-6 in clinical
management of patients, as well as in clinical research,
it is necessary to provide evidence for the reliability and
validity of the HIT-6 in migraine patients who suﬀer
varying headache day frequency. The purpose of this
study was to evaluate the reliability and validity of the
HIT-6 among migraine patients, and its ability in dis-
criminating headache impact and the level of disability
between EM and CM disorders.
Methods
Data sources
Data came from two sources of adult participants with
recent headache complaints: (i) the National Survey of
Headache Impact (NSHI) study (19) and (ii) the HIT-6
Validation (HIT6-V) study (20). The NSHI study was a
1999 telephone interview survey study using a ran-
domly generated list of household telephone numbers
from 48 states of the USA. Eligible participants were:
(i) 18 to 65 years of age; (ii) permanent US residents;
(iii) those with at least one headache in the four weeks
prior to the interview that was not related to a cold, ﬂu,
a head injury or a hangover; and (iv) able to converse
easily in English. Follow-up interviews after three
months were completed for a subgroup of respondents
randomly selected from the initial respondents to rep-
resent mild, moderate and severe headache suﬀerers.
The severity levels associated with pain from headaches
in general were derived based on a numeric rating scale
of headache pain from 0 to 10, 0 representing ‘‘no pain’’
and 10 representing ‘‘pain as bad as it can be.’’ Mild
headache pain was deﬁned by scores 1–4; moderate by
scores 5–7; and severe by scores 8–10. The purpose of
the NSHI study was to obtain empirical data for the
development of the Headache Impact Test item pool
using 54 items from four widely used measures of head-
ache impact, along with 35 new experimental items pro-
posed by clinicians (19,21). The four headache impact
measures were administered in the following order: (i)
the Migraine Disability Assessment (MIDAS) score; (ii)
the Migraine-Speciﬁc Quality of Life (MSQ) question-
naire; (iii) the Headache Impact Questionnaire
(HIMQ); and (iv) the Headache Disability Inventory
(HDI). Details of the NSHI have been described else-
where (19).
Data of the HIT6-V study were collected in 2000
through the America Online (AOL) Opinion Place
from AOL subscribers who were (i) 18 to 65 years of
age, (ii) with at least one headache in the past four
weeks not related to a cold, ﬂu, a head injury or a hang-
over; and (iii) agreed to be contacted again in two weeks
to complete the follow-up survey. At time 1, the HIT-6
was administered ﬁrst followed by the MIDAS and the
QualityMetric’s Short-Form (SF)-8 Health Survey
(which measures eight health domains). At time 2, this
same order was used except that 3 items which assessed
changes in headache impact since time 1 were added
following the MIDAS items and preceding the SF-8.
The purpose of this study was to test the validity of the
HIT-6 in headache suﬀers. Detailed study design of the
HIT6-V has been described elsewhere (20).
In both studies, data were collected on headache
participants. Given the similarities in the inclusion
and exclusion criteria of the two studies and in order
to ensure an adequate sample size in the EM and CM
groups, data from the two studies were pooled when
applicable. For instance, data on the HIT-6 and
MIDAS were collected in both studies, and thus
pooled.
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mation of the six items and ranges between 36 and 78,
with larger scores reﬂecting greater impact. Headache
impact severity level can be categorized using score
ranges based on the HIT-6 interpretation guide (29),
The four headache impact severity categories are little
or no impact (49 or less), some impact (50–55), substan-
tial impact (56–59), and severe impact (60–78).
See Appendix A for the HIT-6 questionnaire.
MIDAS was developed to assess headache-related
disability of migraine patients (30). MIDAS included
ﬁve questions, capturing information on missed days
of work, household chores, non-work activity and
days with substantially reduced productivity over a
three-month period. A total score is calculated by
adding the ﬁve headache-related disability items
together. Higher scores indicate increased disability
due to headache. The total MIDAS score can be
further used to deﬁne four grades of headache-
related disability, including grade I for ‘‘minimal or
infrequent disability’’ (0–5); grade II for ‘‘mild or infre-
quent disability’’ (6–10); grade III for ‘‘moderate dis-
ability’’ (11–20); and grade IV for ‘‘severe disability’’
(21þ) (30). The grades were determined based on phy-
sicians’ judgment of MIDAS scores on varying levels of
migraine patient’s activity limitation and treatment
needs (30). See Appendix B for the MIDAS
questionnaire.
The SF-8 Health Survey is a brief generic health
survey for measuring health-related quality of life
(HRQOL) (31). The SF-8 includes eight questions rep-
resenting the same eight health domains produced by
the SF-36 Health Survey, including physical function-
ing (PF), role limitations due to physical health (RP),
bodily pain (BP), general health (GH), vitality (VT),
social functioning (SF), role limitations due to emo-
tional problems (RE) and mental health (MH).
Weighted scores for these domains can be aggregated
into the physical component summary (PCS) and
mental component summary (MCS) measure scores.
Scoring of the SF-8 used a norm-based approach with
scores centered around 50 reﬂecting the average
domain scores of the general US population (31).
Higher scores indicate better health. Data on the
SF-8 Health Survey were collected in the HIT6-V
study only.
Migraine group classifications
The ID Migraine
TM is an epidemiological migraine
screener that has been reported to be reliable, valid,
and eﬃcient for identifying migraine patients in pri-
mary care (32). Only participants who had values on
ID Migraine and provided the number of headache
days they experienced over the last three months were
included in the current study. Participants were consid-
ered as migraine positive if they met the ID Migraine
criteria. Participants identiﬁed with migraine were fur-
ther grouped based on HDPM (8–10). Those patients
identiﬁed as migraine positive who reported having  15
HDPM were considered to have CM. Those identiﬁed
as migraine positive who responded having <15
HDPM were considered to have EM. The remaining
study participants were classiﬁed as non-migraine head-
ache participants.
Statistical analysis
Internal consistency reliability of the HIT-6 among
migraine participants was assessed by evaluating
Cronbach’s a for the HIT-6 scores across the two stud-
ies and by the pooled sample. A Cronbach’s a value
 0.8 is considered as good internal reliability (33).
Intra-class correlation (ICC) was examined for test-
retest reliability. Because the time interval between
time 1 and time 2 was two weeks in the HIT6-V
study compared to three months in the NSHI study,
test-retest reliability can only be estimated in the
HIT6-V study. ICC values of at least 0.5 were consid-
ered indicative of fair test-retest reliability (34).
Construct validity was assessed through an examina-
tion of the Spearman correlation coeﬃcients between
HIT-6 scores and the SF-8 scores (domains and sum-
mary measures), as well as with the total MIDAS score,
headache pain severity (0–10 scale) and number of
HDPM. We hypothesized that at least small to moder-
ate correlations were present between the HIT-6 scores
and the speciﬁed variables. Assessment of the instru-
ment’s discriminant validity was based on the method
of known-groups validity (35). Known-groups validity
was assessed using analysis of variance (ANOVA)
methods comparing mean HIT-6 score diﬀerences
across CM, EM and non-migraine headache partici-
pants. We expected that higher mean HIT-6 scores
would be observed in the more disabled groups. In
addition, the HIT-6 scores were grouped into four
impact severity categories using the interpretation
guide in the HIT-6 manual (29). Given the directional
nature of the impact severity levels and the headache
staging (i.e. CM, EM, and non-migraine headache),
we hypothesized that non-migraineurs, those with
EM and those with CM would, in that order, have
increasing impact severity level deﬁned by the HIT-6
scores. The proportional odds model was used to
evaluate the hypothesized association. Model adequacy
was assessed using test of proportional odds assump-
tion (36). Other than discriminant validity tests, all
psychometric property assessments were conducted
among the migraine participants (both EM and CM
together).
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A total of 2049 participants were included in the
current study, of which 1096 (53.5%) were from the
NSHI study. A total of 994 participants (48.5% of
the 2049 participants) were identiﬁed as having
migraine, of which 624 (62.8%) were from the NSHI
study. The majority of the participants were female
(75.0%) and slightly over half (56.3%) were between
18 and 39 years of age. Based on the classiﬁcation cri-
teria deﬁned in the "Methods" section above, 6.4% of
the study participants had CM (N¼131) and 42.1%
had EM (N¼863). The rest of participants (51.5%)
had non-migraine headaches (N¼1,055). Participant
characteristics are presented in Table 1.
Approximately half of the participants in the NSHI
and 60% of the participants in the HIT6-V were youn-
ger than 40 years old. Approximately three-quarters
(72.8% in NSHI and 77.4% in HIT6-V) were females.
Reliability analyses
Results of reliability analyses of the HIT-6 among
the migraine suﬀerers are presented in Table 2. The
time interval between the two assessments (time 1 and
time 2) was diﬀerent for the NSHI study and the HIT6-
V study (three months vs. two weeks, respectively).
The internal consistency reliability (Cronbach’s a)
of the HIT-6 was 0.83 at time 1 and 0.87 at time 2
for the NISH study and was 0.82 at time 1 and 0.90
at time 2 for the HIT6-V study. The internal consis-
tency reliability of the pooled migraine sample was
0.83 at time 1 and 0.90 at time 2. The intra-class cor-
relation coeﬃcient for test–retest reliability between
the HIT-6 scores at time 1 and time 2 for the HIT6-V
study was 0.77.
Validity analyses
Correlations between the HIT-6 scores and the total
MIDAS scores, headache pain severity, number of
HDPM, SF-8 scales and the summary measures are
Table 1. Participants’ characteristics and comparisons by episodic and chronic migraine status and study
Non-migraine Episodic migraine Chronic migraine
NSHI
N (%)
HIT6-V
N (%)
NSHI
N (%)
HIT6-V
N (%)
NSHI
N (%)
HIT6-V
N (%)
Age groups*
18–29 114 (24.1) 116 (21.9) 168 (30.4) 80 (27.8) 23 (32.4) 11 (20.8)
30–39 157 (33.3) 126 (23.7) 199 (36.0) 72 (25.0) 25 (35.2) 17 (32.1)
40–49 134 (28.4) 152 (28.6) 128 (23.1) 70 (24.3) 19 (15.3) 19 (35.8)
50–69 67 (14.2) 137 (25.8) 58 (10.5) 66 (22.9) 4 (5.6) 6 (11.3)
Gender
y
Female 298 (63.1) 421 (72.5) 435 (78.7) 269 (87.1) 65 (91.5) 45 (76.3)
Male 174 (36.9) 160 (27.5) 118 (21.3) 40 (12.9) 6 (8.5) 14 (23.7)
HIT6-V: HIT-6 Validation Study. NSHI: National Survey of Headache Impact.
*81 participants had missing value on age.
y4 participants had missing value on gender.
Table 2. Reliability estimates for HIT-6 among migraine
participants
Reliability test Coefficient
Internal consistency reliability
(Cronbach’s a) – NSHI
a
Time 1 0.83
Time 2 0.87
Internal consistency reliability
(Cronbach’s a) – HIT6-V
b
Time 1 0.82
Time 2 0.90
Internal consistency reliability
(Cronbach’s a) – total sample
Time 1 0.83
Time 2 0.90
Test-retest scale reliability – HIT6-V
b 0.77
HIT6-V: HIT-6 Validation Study. NSHI: National Survey of Headache
Impact.
aTime interval between time 1 and time 2 of the NSHI study was
3 months.
bTime interval between time 1 and time 2 of the HIT6-Validation study
was 2 weeks.
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correlated with all of the criteria measures
(p<0.0001) with a small to moderate magnitude, sup-
porting convergent validity. The highest correlation
was observed between the HIT-6 scores and the total
MIDAS scores (r¼0.56) HIT-6 scores and headache
pain intensity were also moderately associated
(r¼0.46), while a lower correlation with the number
of HDPM was observed (r¼0.29).
All correlations with SF-8 scales and summary mea-
sures were negative, as expected. The highest correla-
tions were observed between the HIT-6 and the SF-8
role physical (RP) and social functioning (SF) scales
and the lowest correlations were observed between the
HIT-6 and the SF-8 vitality (VT) and mental health
(MH) scales. In relation to the physical and mental
health summary measures, a higher correlation was
observed with the physical component summary
(PCS-8) than the mental component summary (MCS-8).
In Table 4, the means and standard deviations of the
scores on HIT-6, HDPM, headache pain severity,
MIDAS, PCS-8 and MCS-8 are presented across the
headache groups and the overall study sample.
Results showed that the more severe the headache
status, the worse the values on all of these scales. The
mean HIT-6 scores were signiﬁcantly diﬀerent between
the CM and EM suﬀerers (62.5 7.8 vs. 60.2 7.8,
p¼.0032). In discriminant validity analysis using
groups known to diﬀer in migraine diagnosis and head-
ache frequency as the criterion measure (i.e. CE, EM
and non-migraine headache suﬀerers), the HIT-6
showed large and statistically signiﬁcant diﬀerences in
mean scores across the diagnostic groups (F¼488.02,
p<.0001).
Table 5 shows the frequency and percentage of
HIT-6 impact severity level by CM, EM and non-
migraine headache. Based on the four impact categories
derived from HIT-6 scores, for slightly over half
(51.6%) of the non-migraine participants headache
had little or no adverse impact to their daily life
whereas very few in either migraine where in this
impact category (EM¼10.9%; CM¼7.8%). Over a
half of the EM participants and nearly three-quarters
in the CM groups indicated that their headache had
severe adverse impact on their daily life. In contrast,
only 15.2% of the non-migraine headache participants
indicated that their headache had severe adverse impact
Table 4. Means and standard deviations of the headache measures by groups
Non-migraine EM CM Total sample
N, % 1055, 51.5% 863, 42.1% 131, 6.4% 2,049, 100%
HIT-6*,
  49.1 8.7 60.2 7.8 62.5 7.8 54.6 10.1
HDPM*,
  3.7 4.6 4.7 3.3 21.4 5.8 5.3 6.0
Headache pain severity 4.6 1.9 6.7 1.8 7.1 1.7 5.6 2.2
MIDAS*,
  5.6 9.5 21.0 24.8 52.6 46.5 14.7 23.77
PCS-8*,
  50.4 7.9 46.7 8.9 42.6 10.3 48.0 8.9
MCS-8*,
  47.7 10.0 44.3 10.6 38.8 11.2 45.5 10.7
CM¼chronic migraine. EM¼episodic migraine. HDPM¼headache days per month. MIDAS¼Migraine Disability [assessment scale]. PCS-8¼physical
component summary [SF-8 Health Survey]. MCS-8¼physical component summary [SF-8].
*Means were statistically significantly different (p<0.01) across non-migraine headache, EM and CM groups.
 Means were statistically significantly different (p<0.01) across EM and CM groups.
Table 3. Correlations between HIT-6 scores and migraine
criteria measures in migraine participants
Criterion Measure
Coefficient
(r)
Headache days per month; N¼988) 0.29
Headache pain severity (0–10: N¼986) 0.46
MIDAS total score (N¼926) 0.260
SF-8 Scales
a (N¼624)
Physical functioning  0.24
Role physical  0.29
Bodily pain  0.18
General health  0.20
Vitality  0.17
Social functioning  0.28
Role emotional  0.24
Mental health  0.16
SF-8 summary measures
a (N¼624)
Physical component summary (PCS-8)  0.26
Mental component summary (MCS-8)  0.18
HIT-6¼6-item Headache Impact Test. MIDAS¼Migraine Disability
Assessment scale.
All Spearman correlation coefficients were significant at <0.0001.
aSF-8 data were only collected in the HIT6-Validation study.
Yang et al. 361to their daily life. The proportional odds assumption
was met (X
2¼0.3834, p¼. 9838), validating the use of
the proportional odds model to describe the relation-
ship between frequency based headache groups and
HIT-6 headache impact levels. The model revealed
that when compared to the non-migraine headache suf-
ferers, the odds of reporting one level higher on the
HIT-6 impact severity level were approximately eight
times greater for EM (odds ratio [OR]¼8.6, 95% con-
ﬁdence interval [CI]: 7.3–10.7); and 13 times greater for
CM (OR¼13.4, 95% CI: 9.0–19.9).
Discussion
The clinical community is increasingly interested in
improving the diagnosis and treatment paradigm for
patients with chronic migraine. Although chronic
migraine suﬀerers represent a small subgroup of the
overall migraine population, the annual costs associ-
ated with CM patients (including both direct and indi-
rect costs) are four times more than those with EM on a
per-patient basis (37). Controlled clinical data on acute
and prophylactic treatment of chronic migraine is lim-
ited (13,23) and consequently, there is little evidence-
based medicine available to help physicians care for
these patients. Recently introduced diagnostic criteria
for CM should improve clinicians’ abilities to diagnose
this highly disabling disorder. It is also necessary to
ensure that valid and reliable measures are available
to aid in the clinical evaluation of treatment. The
HIT-6 questionnaire is a simple, easy to administer
assessment that can be used as a clinical evaluation of
the impact of headache on a patient’s quality of life.
Because the HIT-6 was initially developed and vali-
dated in a broad range of headache suﬀers, it is impor-
tant to establish its reliability and validity of the
measure among migraine patients and to determine its
ability to discriminate headache impact and level of
disability between EM and CM.
In this study, the HIT-6 showed high internal con-
sistency reliability among migraine suﬀerers, varying
between 0.82 and 0.90. This is comparable to the orig-
inal development study (0.84–0.90) among the general
headache suﬀerers (20) and to the validation study
among patients in a headache-specialty practice (0.87)
(38). Our study also had similar test-retest reliability
(0.77) to other studies which reported values between
0.77and 0.80 (20,38). Construct validity was supported
by the convergent validity in HIT-6 correlation with the
MIDAS total score headache pain intensity, the
number of HDPM and the negative correlations with
SF-8 scales and summary scores, as well as by the dis-
criminant validity across the diﬀerent stages of head-
ache. The diﬀerence in mean HIT-6 score between
chronic and episodic migraine was smaller (2.3) than
the diﬀerence in mean MIDAS scores (21.6).
Although the diﬀerence provided by MIDAS scores
was nearly 10 times greater than that observed with
the HIT-6, the two instruments do not share the same
scale and thus these values cannot be directly com-
pared. When taking into account the actual scale
ranges, we ﬁnd that the diﬀerence in mean HIT-6
scores between EM and CM patients is equivalent to
roughly 5.5% of the scale range (2.3/[78–36]), whereas
the diﬀerence obtained with the MIDAS is roughly
equivalent to 11.7% (21.6/[270–0]). We note also that
the minimally important diﬀerence of the HIT-6 in
patients with chronic daily headache was estimated to
be between  2.7 and  2.3 (39). Although not oﬀering a
direct comparison to the result observed in the current
study, this range may provide an additional frame of
reference. It is important to note that while the MIDAS
questionnaire and the HIT-6 are both patient-reported
measures, the constructs assessed by the respective
instruments diﬀer. The MIDAS asks suﬀerers to
report the number of missed days of paid work, house-
hold chores and non-work activity as well as reduced
productivity related to headaches, whereas the HIT-6
assesses the extent of headache impact on various
aspects of daily life on a ﬁve-point scale ranging from
never to always. Given that the MIDAS content
focuses on lost time due to headaches and the HIT-6
measures impact of headaches, it is not unexpected that
diﬀerences between EM and CM patients were greater
for MIDAS than for HIT-6 scores. Both instruments
assess important but diﬀerent aspects of headache-
related disability using scales that diﬀer substantially.
While each of the items in the MIDAS provides a more
objective evaluation by asking about frequency of days
aﬀected by headache, the items in the HIT-6 may better
reﬂect patients own evaluation of how headaches
aﬀect their life. This subjective evaluation of disease
Table 5. Frequencies and percentages of headache staging by
HIT-6 Impact severity level*
HIT-6 severity level Non-migraine EM CM
Little or no impact 541 (51.6) 94 (10.9) 10 (7.8)
Some impact 232 (22.1) 109 (12.7) 12 (9.4)
Substantial impact 117 (11.2) 133 (15.5) 16 (12.5)
Severe impact 158 (15.2) 524 (60.9) 90 (70.3)
Total N (%) 1,048 (100) 860 (100) 128 (100)
HIT-6¼6-item Headache Impact Test. CM¼chronic migraine.
EM¼episodic migraine.
Little or no impact¼HIT-6 score 49 or less. Some impact¼HIT-6 score
50–55. Substantial impact¼HIT-6 score 56–59. Severe impact¼HIT-6
score 60.
13 patients with missing value on HIT-6 were excluded in this table.
*Study participants were significantly differently distributed across HIT-6
severity levels (X
2¼607.31, p<.0001)
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patient reported outcomes (PROs), which aim to cap-
ture the impact of a disease on patients’ quality of life.
Moreover, a one-month recall of the HIT-6 may oﬀer a
more accurate evaluation of impact than the three-
month recall used in the MIDAS.
A small correlation coeﬃcient between the HIT-6
and the number of HDPM was also expected. While
it is important clinically to know the number of head-
ache days, such a value only provides headache day
frequency, but it does not reﬂect to what extent head-
ache aﬀects the suﬀerer’s daily life. Our ﬁndings regard-
ing the relative strength of the association between
HIT-6 scores and headache pain intensity and headache
frequency agree with those of another study (40) that
also reported HIT-6 scores to be more strongly associ-
ated with headache pain severity than with headache
frequency. However, in another study (41) headache
frequency, but not headache severity, was strongly
related to HIT-6 scores. In this latter study, pain sever-
ity was measured through headache diaries, whereas
our study and the study of Sauro (40) assessed pain
severity through a single question. This important
methodological diﬀerence may account for the dispar-
ity in ﬁndings. Nevertheless, despite diﬀerences in study
measures used to collect headache characteristics and
headache disability, other studies (42,43) have also
reported that disability was more strongly associated
with headache pain severity than with headache
frequency.
Small negative correlations were observed between
the HIT-6 and the SF-8 scales and summary scores. The
magnitude of these correlations was smaller than the
correlations from another study between the HIT-6
and the SF-36 Health Survey (38). In that study (38),
the negative correlation coeﬃcients varied between 0.22
and 0.57. The highest correlation was observed on the
social functioning (SF) scale (r¼ 0.57), followed by
the role physical (RP) limitation (r¼ 0.52). The weak-
est association was observed on the mental health
(MH) scales (r¼ 0.22). While our study had much
smaller correlation coeﬃcients, a similar order of the
magnitude of the correlations between the HIT-6 and
the SF scale scores were observed where the strongest
association was with RP and SF scales and the weakest
was with the MH scale. The diﬀerences in the magni-
tude of the association between the HIT-6 and the SF-8
versus HIT-6 and the SF-36 are likely due to having
more questions asked in the SF-36. Although, because
it has more questions in each scale, the SF-36 provides
more stable scale scores, additional questions may also
capture aspects of headache impact that were missed in
the SF-8.
Discriminant validity test showed that the HIT-6
scores diﬀered signiﬁcantly across the groups between
CM, EM and non-migraine headache suﬀerers. When
using the HIT-6 interpretation guideline to categorize
the headache impact severity levels, our ﬁndings suggest
that CM suﬀerers were more likely to report substantial
or severe headache impact compared to EM or non-
migraine suﬀerers. However, in a French study of the
HIT-6 (44) similar HIT-6 scores were observed in
chronic ( 15 days; N¼68) and episodic headache
patients (<15 days; N¼75) who were seen in a
migraine clinic (63.1 [time 1] and 62.5 [time 2] for
chronic headache patients vs. 64.9 [time 1] and 62.9
[time 2] for episodic headache patients at time 1 and
time 2, respectively). Diﬀering ﬁndings between studies
are likely due to the smaller size and possibly greater
homogeneity of the sample in the French study.
The ﬁndings from our study have important clinical
implications. As suggested by clinical experts, migraine
is a chronic disorder that in some patients can be char-
acterized as a clinically progressive disorder with
increasing headache frequency (8,9,45). Bigal and
Lipton (8,9) have suggested that migraine chroniﬁca-
tion should look beyond the clinical progression
deﬁned by attack frequency and also take into account
the physiological and anatomical progression of the
disorder. Given that those patients with CM have a
much greater burden of disease and poorer quality of
life (3–7), headache experts suggest that aggressive
treatment should be provided to migraine patients in
order to possibly prevent progression of the disorder
and undo patient suﬀering (10).
A limitation of the study was that the migraine diag-
nosis was not based on physician report, but rather the
participants’ self-report to a validated migraine screen-
ing tool, the ID Migraine Screener (32), was used. It is
possible that some suﬀerers were misclassiﬁed as with
or without migraine. Although the ID Migraine has
demonstrated excellent accuracy properties (32), it is
possible that respondents were misclassiﬁed relative to
IHS diagnostic criteria. The results presented in its val-
idation study, suggested that, the ID Migraine Screener
had a slightly higher misclassiﬁcation (speciﬁcity¼
0.75) among patients who were classiﬁed by the
ICHD-II criteria as not having migraine than among
patients who met ICHD-II criteria for migraine (sensi-
tivity¼0.81). These results suggest that overall our
study could have been overly inclusive with respect to
its identiﬁcation of migraine cases. On the other hand,
the use of ID Migraine Screener could have inﬂuenced,
to some extent, the large diﬀerences in HIT-6 scores
observed between non-migraine and migraine
groups since the presence of disability (interference
with activities) is one of the three items used in the
ID Migraine Screener. Nevertheless, the development
study of the ID Migraine Screener did select these
3 items from a larger pool of 9, suggesting that this
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with IHS criteria. Overall, we feel conﬁdent that the
potential bias caused by the use of the ID Migraine
Screener was, at most, small. Another limitation is
that the study datasets came from two sources (i.e.
the NSHI and HIT6-V). Due to somewhat diﬀerent
designs, some study analyses could only be performed
using one dataset, but not the other. For instance, we
were able to obtain a satisfactory result for test-retest
analysis using the HIT6-V but not with NSHI due to
lack of availability of such data for the test. In addition,
for some tests we had a larger dataset to analyze
because data from both sources were able to be
pooled for analysis.
Conclusion
Our study shows that the HIT-6 is a reliable and valid
tool for measuring the impact of headache on daily life
in both episodic and chronic migraine suﬀerers.
Furthermore, the HIT-6 tool discriminates well
between chronic migraine, episodic migraine and non-
migraine patients. As a brief tool, the HIT-6 is easy to
score and interpret, and can be readily integrated into
clinical practice, or clinical studies of migraine patients.
It may oﬀer clinicians a practical and easy-to-imple-
ment tool to assist them with evaluating treatment
eﬀectiveness by obtaining input directly from the
patient on aspects other than just the frequency of
headache days.
Funding
Support for this study provided by Allergan, Inc.
Acknowledgements
The authors would like to thank Catherine C Turkel,
PharmD, PhD for her helpful comments on the manuscript.
References
1. Rasmussen BK. Epidemiology of migraine. Biomed
Pharmacother 1995; 49: 452–455.
2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML
and Stewart WF. Migraine prevalence, disease burden,
and the need for preventive therapy. Neurology 2007; 68:
343–349.
3. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ and
Sheftell FD. Assessment of migraine disability using the
migraine disability assessment (MIDAS) questionnaire: a
comparison of chronic migraine with episodic migraine.
Headache 2003; 43: 336–342.
4. Lipton RB, Liberman JN, Kolodner KB, Bigal ME,
Dowson A and Stewart WF. Migraine headache disabil-
ity and health-related quality-of-life: a population-based
case-control study from England. Cephalalgia 2003; 23:
441–450.
5. Monzon MJ and Lainez MJ. Quality of life in migraine
and chronic daily headache patients. Cephalalgia 1998;
18: 638–643.
6. Bigal ME, Serrano D, Reed M and Lipton RB. Chronic
migraine in the population: burden, diagnosis, and satis-
faction with treatment. Neurology 2008; 71: 559–566.
7. Stewart WF, Lipton RB and Simon D. Work-related dis-
ability: results from the American migraine study.
Cephalalgia 1996; 16: 231–238.
8. Bigal ME and Lipton RB. Clinical course in migraine:
conceptualizing migraine transformation. Neurology
2008; 71: 848–855.
9. Bigal ME and Lipton RB. Concepts and mechanisms of
migraine chronification. Headache 2008; 48: 7–15.
10. Lipton RB and Bigal ME. Looking to the future: research
designs for study of headache disease progression.
Headache 2008; 48: 58–66.
11. Ferrari A, Leone S, Vergoni AV, et al. Similarities and
differences between chronic migraine and episodic
migraine. Headache 2007; 47: 65–72.
12. Lipton RB, Diamond S, Reed M, Diamond ML and
Stewart WF. Migraine diagnosis and treatment: results
from the American Migraine Study II. Headache 2001;
41: 638–645.
13. Headache Classification Committee of the International
Headache Society. International classification of head-
ache disorders, 2nd edn. Cephalalgia 2004; 24: 9–160.
14. Headache Classification Committee of the International
Headache Society. New appendix criteria open for a
broader concept of chronic migraine. Cephalalgia 2006;
26: 742–746.
15. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for
controlled trials of drugs in migraine, 2nd edn.
Cephalalgia 2000; 20: 765–786.
16. Andrasik F, Lipchik GL, McCrory DC and Wittrock
DA. Outcome measurement in behavioral headache
research: headache parameters and psychosocial out-
comes. Headache 2005; 45: 429–437.
17. Turk DC, Dworkin RH, Allen RR, et al. Core outcome
domains for chronic pain clinical trials: IMMPACT rec-
ommendations. Pain 2003; 106: 337–345.
18. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guide-
lines for controlled trials of prophylactic treatment of
chronic migraine in adults. Cephalalgia 2008; 28:
484–495.
19. Ware Jr JE, Bjorner JB and Kosinski M. Practical
implications of item response theory and computerized
adaptive testing: a brief summary of ongoing studies of
widely used headache impact scales. Med Care 2000; 38:
73–82.
364 Cephalalgia 31(3)20. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item
short-form survey for measuring headache impact: the
HIT-6. Qual Life Res 2003; 12: 963–974.
21. Bjorner JB, Kosinski M and Ware Jr JE. Using item
response theory to calibrate the Headache Impact Test
(HIT
TM
) to the metric of traditional headache scales.
Qual Life Res 2003; 12: 981–1002.
22. De Diego EV and Lanteri-Minet M. Recognition and
management of migraine in primary care: influence of
functional impact measured by the headache impact test
(HIT). Cephalalgia 2005; 25: 184–190.
23. Diener H, Bussone G, Van Oene J, Schwalen S and
Goadsby PJ. Topiramate reduces headache days in
chronic migraine: a randomized, double-blind, placebo-
controlled study. Cephalalgia 2007; 27: 814–823.
24. Jelinski S, Becker W, Christie S, et al. Clinical features
and pharmacological treatment of migraine patients
referred to headache specialists in Canada. Can J
Neurol Sci 2006; 33: 228–234.
25. Nachit-Ouinekh F, Dartigues JF, Henry P, et al. Use of
the headache impact test (HIT-6) in general practice: rela-
tionship with quality of life and severity. Eur J Neurol
2005; 12: 189–193.
26. El HA, Doble A and Gaudin AF. [Tools for assessing
patient perception of the impact of migraine]. [French.].
CNS Drugs 2006; 20(1): 24–36.
27. Cady R and Schreiber C. Botulinum toxin type A as
migraine preventive treatment in patients previously fail-
ing oral prophylactic treatment due to compliance issues.
Headache 2008; 48: 900–913.
28. Lanteri-Minet M, Massiou H, Nachit-Ouinekh F,
Pradalier A and Radat F. The GRIM2005 study of
migraine consultation in France I. Determinants of con-
sultation for migraine headache in France. Cephalalgia
2007; 27: 1386–1397.
29. Bayliss M and Batenhorst A. The HIT-6
TM: a user’s
guide. USA: QualityMetric, Inc: Lincoln, RI, 2002.
30. Stewart WF, Lipton RB, Dowson AJ and Sawyer J.
Development and testing of the Migraine Disability
Assessment (MIDAS) Questionnaire to assess headache-
related disability. Neurology 2001; 56: 20–28.
31. Ware Jr JE, Kosinski M, Dewey JE, Gandek B. How to
score and interpret single-item health status measures: a
manual for users of the SF-8 Health Survey. (With a sup-
plement on the SF-6 Health Survey). QualityMetric, Inc:
Lincoln, RI, USA, 2001.
32. Lipton RB, Dodick D, Sadovsky R, et al. A self-
administered screener for migraine in primary care: The
ID Migraine validation study. Neurology 2003; 61:
375–382.
33. Nunnally JC and Bernstein IH. Psychometric theory, 3rd
edn. New York: McGraw-Hill, 1994.
34. Shrout PE and Fleiss JL. Intraclass correlations: uses in
assessing rater reliability. Psychol Bull 1979; 86: 420–428.
35. Kerlinger F. Foundations of behavioral research. New
York: Holt, Rinehart & Winston, 1973.
36. Brandt R. Assessing the proportionality on the propor-
tional odds model for ordinal logistic regression.
Biometrics 1990; 46: 1171–1178.
37. Munakata J, Hazard E, Serrano D, et al. Economic
burden of transformed migraine: results from the Amer-
ican Migraine Prevalence and Prevention (AMPP) Study.
Headache 2009; 49: 498–508.
38. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG,
Mann JD and Kahn K. Psychometric properties of the
HIT-6 among patients in a headache-specialty practice.
Headache 2005; 45: 638–643.
39. Coeytaux RR, Kaufman JS, Chao R, Mann JD and
Devellis RF. Four methods of estimating the minimal
important difference score were compared to establish a
clinically significant change in Headache Impact Test.
J Clin Epidemiol 2006; 59: 374–380.
40. Sauro KM, Rose MS, Becker WJ, et al. HIT-6 and
MIDAS as measures of headache disability in a headache
referral population. Headache 2010; 50: 383–395.
41. Shin HE, Park JW, Kim YI and Lee KS. Headache
Impact Test-6 (HIT-6) Scores for Migraine Patients:
Their Relation to Disability as Measured from a Head-
ache Diary. J Clin Neurol 2008; 4: 158–163.
42. Magnusson JE and Becker WJ. Migraine frequency and
intensity: relationship with disability and psychological
factors. Headache 2003; 43: 1049–1059.
43. Jacobson GP, Ramadan NM, Aggarwal SK and
Newman CW. The Henry Ford Hospital Headache
Disability Inventory (HDI) 2. Neurology 1994; 44:
837–842.
44. Magnoux E, Freeman MA and Zlotnik G. MIDAS and
HIT-6 French translation: reliability and correlation
between tests. Cephalalgia 2008; 28: 26–34.
45. Haut SR, Bigal ME and Lipton RB. Chronic disorders
with episodic manifestations: focus on epilepsy and
migraine. Lancet Neurol 2006; 5: 148–157.
Yang et al. 365Appendix A
The HIT-6 is a copyright of QualityMetric Incorporated.
HIT-6
TM  HEADACHE IMPACT TEST
This questionnaire was designed to help you describe and communicate the way you feel and what you 
cannot do because of headaches. 
To complete, please check one box for each question. 
1. When you have headaches, how often is the pain severe? 
 Never   Rarely   Sometimes   Very Often   Always 
2. How often do headaches limit your ability to do usual daily activities including household 
work, work, school, or social activities? 
 Never   Rarely   Sometimes   Very Often   Always 
3. When you have a headache, how often do you wish you could lie down? 
 Never   Rarely   Sometimes   Very Often   Always 
4. In the past 4 weeks, how often have you felt too tired to do work or daily activities because of your 
headaches? 
 Never   Rarely   Sometimes   Very Often   Always 
5. In the past 4 weeks, how often have you felt fed up or irritated because of your headaches? 
 Never   Rarely   Sometimes   Very Often   Always 
6. In the past 4 weeks, how often did headaches limit your ability to concentrate on work or daily 
activities? 
 Never   Rarely   Sometimes   Very Often   Always 
  COLUMN 1  COLUMN 2  COLUMN 3  COLUMN 4  COLUMN 5 
  (6 points each)  (8 points each)  (10 points each)  (11 points each)  (13 points each) 
To score, add points for answers in each column 
Please share your HIT-6 results with your doctor.
Total Score:_____________  
Higher scores indicate 
greater impact on your life. 
Score range is 36-78.
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With reprint permission from CVS Caremark for use as an Appendix in this paper
The Migraine Disability Assessment Test
The MIDAS (Migraine Disability Assessment) questionnaire was put together to help you measure the 
impact your headaches have on your life. The information on this questionnaire is also helpful for your 
primary care provider to determine the level of pain and disability caused by your headaches and to find 
the best treatment for you.
INSTRUCTIONS
Please answer the following questions about ALL of the headaches you have had over the last 3 months. 
Select your answer in the box next to each question. Select zero if you did not have the activity in the last 
3 months. 
__________ 1. On how many days in the last 3 months did you miss work or school 
because of your headaches? 
__________ 2. How many days in the last 3 months was your productivity at work or 
school reduced by half or more because of your headaches? (Do not 
include days you counted in question 1 where you missed work or 
school.)
__________ 3. On how many days in the last 3 months did you not do household work 
(such as housework, home repairs and maintenance, shopping, caring 
for children and relatives) because of your headaches? 
__________ 4. How many days in the last 3 months was your productivity in household 
work reduced by half of more because of your headaches? (Do not 
include days you counted in question 3 where you did not do household 
work.)
__________ 5. On how many days in the last 3 months did you miss family, social or 
leisure activities because of your headaches? 
__________        Total (Questions 1-5)
__________ A. On how many days in the last 3 months did you have a headache? (If a 
headache lasted more than 1 day, count each day.) 
__________ B. On a scale of 0 - 10, on average how painful were these headaches?
(where 0 = no pain at all, and 10 = pain as bad as it can be.) 
MIDAS
Grade Definition MIDAS
Score
I Little or no disability 0-5
II Mild disability 6-10
III Moderate disability 11-20
Scoring: After you have 
filled out this questionnaire, 
add the total number of 
days from questions 1-5
(ignore A and B)
IV Severe disability 21+
Please give the completed form to your clinician.
This survey was developed by Richard B. Lipton, MD, Professor of Neurology, Albert Einstein College of Medicine, New York, NY, 
and Walter F. Stewart, MPH, PhD, Associate Professor of Epidemiology, Johns Hopkins University, Baltimore, MD.
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